Léčivé přípravky s obsahem účinné látky Apadamtasa alfa a cinaxadamtasa alfa
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
25 / 100
Risk factors
Eligibility criteria, required documents, and detailed specifications are not provided in the structured data or XML no...
Award based on lowest price may lead to aggressive pricing and potential quality concerns, but this is explicit and acc...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- CZK 23.3M estimated value
- Supplies contract
- 1 lot
- Duration 2 YEAR
- Supply of medicinal products with active substances Apadamtasa alfa and cinaxadamtasa alfa, 1500 IU per vial.
- Packaging: 1 vial + 5 ml solvent + Baxject + straw.
Show full summary
Open tender for the supply of medicinal products containing active substances Apadamtasa alfa and cinaxadamtasa alfa (1500 IU) to Krajská nemocnice Liberec, a.s., Czech Republic. Single lot, duration 2 years, estimated value 23,302,000 CZK. Award based on lowest price.
Risks
Eligibility criteria, required documents, and detailed specifications are not provided in the structured data or XML no...
Award based on lowest price may lead to aggressive pricing and potential quality concerns, but this is explicit and acc...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Tender must include a price offer for the total estimated quantity over 2 years.
Administrative
- Tenders must be submitted electronically via the provided submission URL.
- Submission language: Czech.
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Name
Krajská nemocnice Liberec, a.s.
Location
Liberec, CZE
Website
Buyer profile
Identifier
27283933
Lots (1)
LOT-0001
Léčivé přípravky s obsahem účinné látky Apadamtasa alfa a cinaxadamtasa alfa
Continuous supply of medicinal products with active substances Apadamtasa alfa and cinaxadamtasa alfa, strength 1500 IU in injection vial, packaging 1+5ML+BAXJECT+STŘ. Delivery based on partial orders over 2 years.
CZK 23.3M
Estimated value
Location
Duration
Category
Selection criteria
Deadline
Award details
Additional CPV codes
Value note
Show original TED data
Original TED description
Předmětem veřejné zakázky jsou průběžné dodávky léčivých přípravků s obsahem účinné látky Apadamtasa alfa a cinaxadamtasa alfa o síle 1500IU v injekční lahvičce v balení 1+5ML+BAXJECT+STŘ (dále jen „léčivé přípravky“ nebo také „zboží“). Specifikace požadovaného léčivého přípravku je uvedena v ZD a ve formuláři cenové nabídky, který je přílohou č. 2 této ZD. Průběžné dodávky léčivých přípravků budou uskutečňovány na základě dílčích objednávek vystavovaných dle aktuálních potřeb zadavatele po dobu dvou let ode dne nabytí účinnosti Kupní smlouvy.
Procurement Details
- Publication date
- 08 Jun 2026
- Notice type
- Contract notice — standard
- Languages
- Czech
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 392562-2026
- Source notice ID
- b7a049c3-a850-435d-aa19-733754cecf0e
Documents (2)
Similar tenders
Romania – Various medicinal products – Acor Cadru de Furnizare Diverse Medicamente si Ambalaje Farmaceutice
Poland – Various medicinal products – ZP.220.99.26 Dostawa różnych produktów leczniczych, żywności medycznej oraz preparatów do żywienia pacjentów na potrzeby
Poland – Pharmaceutical products – Dostawa produktów leczniczych do SPZZOZ w Wyszkowie
Poland – Antineoplastic agents – Dostawa produktów leczniczych i wyrobów medycznych do Wojskowego Instytutu Medycznego – PIB
Poland – Antineoplastic agents – Leki onkologiczne i sprzęt pomocniczy
Poland – Antithrombotic agents – Dostawa produktów leczniczych do leczenia zaburzeń w funkcjonowaniu przewodu pokarmowego, środków antybakteryjnych do użytku ogólnoustrojowego (...) w podziale na 21 części.
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
25 / 100
Risk factors
Eligibility criteria, required documents, and detailed specifications are not provided in the structured data or XML no...
Award based on lowest price may lead to aggressive pricing and potential quality concerns, but this is explicit and acc...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications